StockIQ.techThermo Fisher Scientific Inc. (TMO) Stock Analysis
Free AI-powered analysis and research for Thermo Fisher Scientific Inc. stock
Sector: Healthcare
TMO snapshot
Data as of 3 Nov 2026 close. Updated daily.
Thermo Fisher Scientific Inc. scores 66/100 on StockIQ's model, which reads as positive signals overall. The price is above its 200-day average and at 95% of its 52-week range, up 23.3% over the past year. Latest reported figures show a profit margin of 14.9%, return on equity of 13.4% and revenue growth of +9.1%.
What is driving the score
- RSI Neutral: +5
- Strong Uptrend: +12
- MACD Bearish: -8
- High P/E (37.1): -10
- Good Profit Margin (14.9%): +5
- Strong Long-term Uptrend: +8
- Healthy Momentum (+23.3% over 1 year): +7
- Low Volume (0.3x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full TMO report
Thermo Fisher Scientific Inc. (TMO) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze TMO Now →📰 Latest Update
Biobanks - Global Strategic Business Report: Capitalize on a US$51.7 Billion Revenue Surge by 2030 as Thermo Fisher Scientific, Merck KGaA, BioLifeSolutions, and Tecan Reshape the Market
Tue, November 3, 2026 at 3:11 PM UTC 3 min read
The global biobanks market, valued at US$91.6 billion in 2024, is projected to reach US$143.3 billion by 2030, growing at a CAGR of 7.7%. Key drivers include advancements in precision medicine, genomic research, and automated biobanking, alongside rising demand for high-quality biological specimens. The report highlights the impact of global tariff developments on the market and emphasizes the importance of partnerships among academic institutions, healthcare organizations, and life sciences companies in fostering biobank growth and innovation.